N-[(1R,3S)-3-[[2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-yl]amino]cyclohexyl]acetamide

ID: ALA3317981

Chembl Id: CHEMBL3317981

Cas Number: 1259278-19-7

PubChem CID: 68007547

Max Phase: Preclinical

Molecular Formula: C19H20ClFN6O

Molecular Weight: 402.86

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CC(=O)N[C@@H]1CCC[C@H](Nc2nc(-c3c[nH]c4ncc(Cl)cc34)ncc2F)C1

Standard InChI:  InChI=1S/C19H20ClFN6O/c1-10(28)25-12-3-2-4-13(6-12)26-19-16(21)9-24-18(27-19)15-8-23-17-14(15)5-11(20)7-22-17/h5,7-9,12-13H,2-4,6H2,1H3,(H,22,23)(H,25,28)(H,24,26,27)/t12-,13+/m1/s1

Standard InChI Key:  CZGYWJKCWSHMMR-OLZOCXBDSA-N

Associated Targets(non-human)

Influenza A virus (11224 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PB2 Polymerase basic protein 2 (86 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 402.86Molecular Weight (Monoisotopic): 402.1371AlogP: 3.67#Rotatable Bonds: 4
Polar Surface Area: 95.59Molecular Species: NEUTRALHBA: 5HBD: 3
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: 12.66CX Basic pKa: 2.61CX LogP: 2.60CX LogD: 2.60
Aromatic Rings: 3Heavy Atoms: 28QED Weighted: 0.62Np Likeness Score: -1.07

References

1. Clark MP, Ledeboer MW, Davies I, Byrn RA, Jones SM, Perola E, Tsai A, Jacobs M, Nti-Addae K, Bandarage UK, Boyd MJ, Bethiel RS, Court JJ, Deng H, Duffy JP, Dorsch WA, Farmer LJ, Gao H, Gu W, Jackson K, Jacobs DH, Kennedy JM, Ledford B, Liang J, Maltais F, Murcko M, Wang T, Wannamaker MW, Bennett HB, Leeman JR, McNeil C, Taylor WP, Memmott C, Jiang M, Rijnbrand R, Bral C, Germann U, Nezami A, Zhang Y, Salituro FG, Bennani YL, Charifson PS..  (2014)  Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2.,  57  (15): [PMID:25019388] [10.1021/jm5007275]

Source